Evolent program achieves 20% reduction in use of low-value oncology regimens [Yahoo! Finance]
Evolent Health, Inc Class A (EVH)
Last evolent health, inc class a earnings: 2/25 04:02 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.evolenthealth.com
Company Research
Source: Yahoo! Finance
Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens. One low-value regimen costs about 70 times more than a clinically equivalent alternative. WASHINGTON April 15, 2025 /PRNewswire/ -- When treating patients with cancer, oncologists typically can choose from multiple FDA-approved regimens, or combinations of drugs. While tools such as Evolent's clinical pathways can help them find high-value options, providers have not had similar resources to flag regimens on the opposite side of the spectrum. These other regimens may be associated with lower survival, more severe side effects, or extremely high cost without additional clinical benefits. Today, in the Journal of Clinical Pathways, Evolent oncology experts reported on their efforts to identify these "low-value regimens" and then decrease their use by more than 20%, following a multifaceted provider education and engagement campaign with a national payer pa
Show less
Read more
Impact Snapshot
Event Time:
EVH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVH alerts
High impacting Evolent Health, Inc Class A news events
Weekly update
A roundup of the hottest topics
EVH
News
- Evolent Health (NYSE:EVH) was given a new $6.00 price target on by analysts at Piper Sandler.MarketBeat
- Evolent Health (NYSE:EVH) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Evolent Health (NYSE:EVH) had its price target lowered by analysts at Citigroup Inc. from $11.50 to $9.50. They now have a "buy" rating on the stock.MarketBeat
- Evolent Health, American Oncology Network Partner to Streamline Cancer Care [Yahoo! Finance]Yahoo! Finance
- Evolent Health (NYSE:EVH) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
EVH
Earnings
- 11/6/25 - Beat
EVH
Sec Filings
- 12/12/25 - Form 3
- 12/8/25 - Form 8-K
- 12/2/25 - Form 8-K
- EVH's page on the SEC website